Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 13Breast Neoplasms, Male 3Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Intraductal, Noninfiltrating 2Recurrence 1Pancreatic Cyst 1Osteosarcoma 1Inflammatory Breast Neoplasms 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Glioblastoma 1Gastrointestinal Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Carcinoma In Situ 1Brain Neoplasms 1Advanced Cancer 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Tamoxifen × Clear all
NCT00001436 2008-03-04

A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
24 enrolled
Sarcoma

Neoplasm Metastasis, Recurrence, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡